Abstract
Objective: There is an urgent need to assess the impact of immunosuppressive therapies on the immunogenicity and efficacy of SARS-CoV-2 vaccination.
Methods: Serological and T-cell ELISpot assays were used to assess the response to first-dose and second-dose SARS-CoV-2 vaccine (with either BNT162b2 mRNA or ChAdOx1 nCoV-19 vaccines) in 140 participants receiving immunosuppression for autoimmune rheumatic and glomerular diseases.
Results: Following first-dose vaccine, 28.6% (34/119) of infection-naïve participants seroconverted and 26.0% (13/50) had detectable T-cell responses to SARS-CoV-2. Immune responses were augmented by second-dose vaccine, increasing seroconversion and T-cell response rates to 59.3% (54/91) and 82.6% (38/46), respectively. B-cell depletion at the time of vaccination was associated with failure to seroconvert, and tacrolimus therapy was associated with diminished T-cell responses. Reassuringly, only 8.7% of infection-naïve patients had neither antibody nor T-cell responses detected following second-dose vaccine. In patients with evidence of prior SARS-CoV-2 infection (19/140), all mounted high-titre antibody responses after first-dose vaccine, regardless of immunosuppressive therapy.
Conclusion: SARS-CoV-2 vaccines are immunogenic in patients receiving immunosuppression, when assessed by a combination of serology and cell-based assays, although the response is impaired compared with healthy individuals. B-cell depletion following rituximab impairs serological responses, but T-cell responses are preserved in this group. We suggest that repeat vaccine doses for serological non-responders should be investigated as means to induce more robust immunological response.
Keywords: B-lymphocytes; COVID-19; autoimmune diseases; rituximab; vaccination.
【저자키워드】 COVID-19, vaccination, rituximab, Autoimmune diseases, B-lymphocytes, 【초록키워드】 SARS-CoV-2, Efficacy, Vaccine, vaccination, immunogenicity, therapy, Diseases, Lymphocytes, Vaccines, serology, antibody, SARS-COV-2 infection, Antibody Response, T-cell Response, Immunosuppression, SARS-CoV-2 vaccines, SARS-CoV-2 vaccine, rituximab, vaccine dose, BNT162b2, Seroconversion, immune responses, response, Patient, Autoimmune, Autoimmune diseases, serological, ChAdOx1, ChAdOx1 nCoV-19, T-cell responses, SARS-CoV-2 vaccination, BNT162b2 mRNA, immunosuppressive therapy, B-lymphocytes, B-cell, Immunological response, tacrolimus, Evidence, Combination, immunosuppressive, evidence of, glomerular diseases, immunosuppressive therapies, ChAdOx1 nCoV-19 vaccines, failure, healthy individuals, participant, immunogenic, responders, seroconvert, responses, non-responder, robust, T-cell ELISpot, assays, investigated, detectable, receiving, seroconverted, were used, induce, impair, glomerular, mounted, preserved, 【제목키워드】 Patient, receiving,